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EDITORIAL
Revisiting the Potential of EEG Neurofeedback for Patients With Schizophrenia
Fiza Singh*,1, I-Wei Shu1, Eric Granholm1, and Jaime A. Pineda2
1Department of Psychiatry, University of California San Diego, La Jolla, CA; 2Department of Cognitive Science, Division of Cognitive 
Neuroscience, University of California at San Diego, La Jolla, CA
*To whom correspondence should be addressed; Department of Psychiatry, MC 0737, University of California San Diego, 9500 Gilman 
Drive, La Jolla, CA 92093-0810, US; tel: 858-922-4365, e-mail: fsingh@health.ucsd.edu
Schizophrenia (SCZ) is a neurodevelopmental dis-
order that can present as early as late adolescence with 
symptoms such as hallucinations, delusions, social with-
drawal, anhedonia, and deficits in attention and memory. 
Treatment generally consists of pharmacotherapy with 
dopamine antagonists, which are highly effective in re-
ducing positive symptoms, especially during acute epi-
sodes of psychosis. However, negative symptoms (eg, 
social withdrawal, anhedonia) and cognitive deficits tend 
to persist and are associated with profound functional 
decline. Given these realities, novel approaches are re-
quired to develop new treatments for patients with schiz-
ophrenia, especially those targeting unmet therapeutic 
needs. Recent developments suggest that within the 
emerging field of neuromodulation exists a potentially 
promising old, yet new, approach.
Neuromodulation refers to treatments that directly 
target neural or brain signals. For instance, direct and 
alternating current stimulation, deep brain stimulation, 
vagal nerve stimulation, transcranial magnetic stimu-
lation, electroconvulsive therapy, and neurofeedback 
(NFB) are examples of  neuromodulatory interventions. 
In this category of  treatments that include both newer 
and older modalities, NFB occupies a unique position. 
NFB, or biofeedback to brain targets, was first intro-
duced (separately) in the 1960s by Joseph Kamiya1 and 
Barry Sterman.2 Kamiya discovered that subjects could 
modulate their brain activity (as measured by electro-
encephalography, or EEG) in response to simple re-
wards. Sterman initially trained cats to control their 
brainwaves,2 and subsequently went on to use NFB to 
train patients with epilepsy to lower seizure activity.3 In 
the years since, many different, primarily EEG-guided, 
protocols have been developed to address several dis-
orders, including attention deficit hyperactivity disorder 
(ADHD), depression, post-traumatic stress disorder, 
and schizophrenia, among others.4 In brief, these 
NFB protocols generally enable individuals to prac-
tice modulating their own brain activity, by consciously 
manipulating visual or auditory representations of 
their EEG activity.5 NFB is unique in that an individual 
uses his or her own strategy to achieve success, which 
inherently allows for individual differences and a flex-
ible, personalized treatment approach. Furthermore, 
NFB is associated with structural changes in brain 
composition, such as increase in grey matter volume of 
the target area,6 suggesting that treatment effects likely 
involve cortical growth and plasticity.
Thus, in light of NFB’s unique ability to unlock the 
brain’s neuroplasticity in an individualized manner, our 
group is developing NFB based treatments for cognitive 
symptoms in SCZ. As part of this project, we conducted 
a systematic review of the literature for studies of NFB 
in patients with schizophrenia, the details of which are 
presented in our accompanying paper in Schizophrenia 
Bulletin Open. To date, few NFB studies have been con-
ducted in schizophrenia spectrum disorders. Nonetheless, 
as a whole, available studies suggest that NFB influences 
neural processing, connectivity, and metabolism in the 
brain and that the effects last well beyond the treatment 
period. The effects also appear to generalize to related 
behavioral, biological, and clinical outcomes and are ob-
served even during periods when subjects are asked to 
reproduce the neuromodulatory skills they have learned 
outside of formal feedback. Finally, of special impor-
tance for patients with complex treatment requirements, 
NFB is generally well tolerated and has a good safety 
profile.
Another major strength of  NFB and other 
neuromodulation techniques comes from the fact that 
they can be designed to target specifically and objectively 
defined biological targets. By identifying and treating 
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network- or circuit-specific impairments, treatments 
are no longer symptom- or syndrome-centric, and can 
therefore be applied across DSM diagnostic categories. 
Furthermore, careful study of  the brain’s responses to 
these treatments can also advance mechanistic under-
standing of  brain-based disorders and treatments, po-
tentially unlocking novel therapeutic approaches. The 
review also revealed that current knowledge of  NFB 
comes from small, case control studies, and that larger, 
randomized, placebo-controlled trials are needed.
Thus, given the potential promise of NFB and related 
neuromodulatory approaches as discussed above, we hope our 
proposal helps other investigators to further develop their own 
research programs to bring neuroscientifically driven, clinically 
feasible treatments closer to patients in the real world—ulti-
mately improving speeds and rates of recovery, and the lives 
of patients suffering from these disabling and costly, disorders.
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